[go: up one dir, main page]

MX2024006009A - Metodo para aliviar el estres oxidativo. - Google Patents

Metodo para aliviar el estres oxidativo.

Info

Publication number
MX2024006009A
MX2024006009A MX2024006009A MX2024006009A MX2024006009A MX 2024006009 A MX2024006009 A MX 2024006009A MX 2024006009 A MX2024006009 A MX 2024006009A MX 2024006009 A MX2024006009 A MX 2024006009A MX 2024006009 A MX2024006009 A MX 2024006009A
Authority
MX
Mexico
Prior art keywords
oxidative stress
fatty acid
alleviating oxidative
derivative
alleviating
Prior art date
Application number
MX2024006009A
Other languages
English (en)
Inventor
Tadaomi Naka
Wakako Seki
Seizo Sato
Original Assignee
Nissui Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissui Corp filed Critical Nissui Corp
Publication of MX2024006009A publication Critical patent/MX2024006009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un método para tratar o prevenir un trastorno relacionado con el estrés oxidativo, comprendiendo el método administrar una cantidad eficaz de un ácido graso poliinsaturado de cadena muy larga (VLC-PUFA), un derivado farmacéuticamente funcional del mismo o una sal farmacéuticamente aceptable del mismo a un sujeto que necesita el tratamiento o la prevención.
MX2024006009A 2021-12-03 2022-11-30 Metodo para aliviar el estres oxidativo. MX2024006009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163285669P 2021-12-03 2021-12-03
PCT/JP2022/044201 WO2023100938A1 (ja) 2021-12-03 2022-11-30 酸化ストレス緩和方法

Publications (1)

Publication Number Publication Date
MX2024006009A true MX2024006009A (es) 2024-08-09

Family

ID=86612335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006009A MX2024006009A (es) 2021-12-03 2022-11-30 Metodo para aliviar el estres oxidativo.

Country Status (8)

Country Link
US (1) US20250032438A1 (es)
EP (1) EP4442259A4 (es)
JP (1) JPWO2023100938A1 (es)
KR (1) KR20240112271A (es)
CN (1) CN118524834A (es)
CA (1) CA3239555A1 (es)
MX (1) MX2024006009A (es)
WO (1) WO2023100938A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0786087B2 (ja) * 1991-12-04 1995-09-20 道夫 山本 抗癌剤
WO2009133586A1 (ja) * 2008-04-28 2009-11-05 有限会社アンティアンティ アルツハイマー病の治療医薬
EP2459510A4 (en) * 2009-07-29 2013-08-07 Phenomenome Discoveries Inc HYDROXIDE-FATTY ACID COMPOSITIONS AND USES THEREOF FOR ILLNESS TREATMENT AND DIAGNOSIS
EP3536317A1 (en) 2009-10-30 2019-09-11 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
US20130190399A1 (en) 2009-10-31 2013-07-25 Martek Biosciences Corporation Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
EP2540292A1 (en) 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
SG10201803827UA (en) * 2013-12-04 2018-06-28 Nippon Suisan Kaisha Ltd Microbial oil, production method for microbial oil, concentrated microbial oil, and production method for concentrated microbial oil
AU2016219517B2 (en) 2015-02-09 2020-02-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
US10252972B2 (en) 2015-06-30 2019-04-09 Bizen Chemical Co., Ltd. Synthesis of long-chain unsaturated fatty acid by chemical reaction of carbon chain extension
JP6788381B2 (ja) 2016-05-30 2020-11-25 岩手県 酸化ストレス抑制剤
WO2018175288A1 (en) * 2017-03-20 2018-09-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2020206448A1 (en) 2019-04-04 2020-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2021046448A1 (en) * 2019-09-04 2021-03-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
EP4117652A1 (en) * 2020-03-11 2023-01-18 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising very long chain fatty acids
WO2022140418A1 (en) * 2020-12-21 2022-06-30 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Also Published As

Publication number Publication date
CN118524834A (zh) 2024-08-20
WO2023100938A1 (ja) 2023-06-08
EP4442259A4 (en) 2025-11-26
CA3239555A1 (en) 2023-06-08
KR20240112271A (ko) 2024-07-18
US20250032438A1 (en) 2025-01-30
JPWO2023100938A1 (es) 2023-06-08
EP4442259A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
PH12022552263A1 (en) Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MX2016001593A (es) Composicion de enzima digestiva adecuada para administracion enterica.
MX2023013245A (es) Rescorcinoles, metodos para su fabricacion, y usos de los mismos.
MX2017015456A (es) Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
PH12021551510A1 (en) Steroid compounds, uses and process for preparation therefor
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
ZA202304134B (en) A magl inhibitor
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
WO2022268935A3 (en) Process for the preparation of nlrp3 inhibitors
MX2025007384A (es) Inhibidores de malt1
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
ZA202002103B (en) Compounds as mpges-1 inhibitors
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2024006009A (es) Metodo para aliviar el estres oxidativo.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
EP4461362A3 (en) Nk1-antagonist combination and method for treating synucleinopathies
MX2025000673A (es) Metodos de administracion de nalbufina